An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

類似資料

• Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
  著者:: Asselah, Tarik, 等
  出版事項: (2017)
• Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report
  著者:: Tamaki, Katsuyoshi, 等
  出版事項: (2015)
• Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
  著者:: Marra, Fiona, 等
  出版事項: (2018)
• Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done?
  著者:: Jensen, Donald M.
  出版事項: (2009)
• Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
  著者:: Asselah, Tarik, 等
  出版事項: (2019)